EANS-News: Joint Committee on Vaccination and Immunization (JCVI) in the UK broadens Japanese Encephalitis immunization recommendation to include Intercell vaccine

.
» First country specific recommendation in Europe
» Key to foster
product awareness for Intercell's vaccine to prevent
Japanese
Encephalitis

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Company Information

Subtitle: .
» First country specific recommendation in Europe
» Key to foster product awareness for Intercell's vaccine to prevent
Japanese Encephalitis

Vienna (Austria), March 4, 2010 (euro adhoc) - Intercell AG (VSE:
ICLL) today announced that Joint Committee on Vaccination and
Immunization (JCVI) in the UK has recently updated the Japanese
Encephalitis chapter of Immunisation against infectious diseases
("Green Book") to recommend the use of IXIARO® for individuals aged
18 years and older to protect individuals for high risk of exposure
during travel or in the course of their occupation. This decision
follows the expanded recommendations of the US Advisory Committee on
Immunization Practices (ACIP) in 2009. Further national specific
recommendations in Europe are expected for the year 2010.

"We are pleased that our joint medical management efforts with our
partner Novartis are materializing now also in Europe with the first
country specific recommendations. Especially for novel travel
vaccines recommendations are key to foster disease and product
awareness and thus increasing vaccination rates and product uptake,"
stated Gerd Zettlmeissl, Chief Executive Officer of Intercell.

Intercell's novel Japanese Encephalitis vaccine is a purified,
inactivated vaccine for active immunization of adults against the
Japanese Encephalitis virus.

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: Intercell AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Intercell AG

Lucia Malfent

Global Head Corporate Communications

Tel. +43 1 20620-1303

communications@intercell.com

Branche: Biotechnology
ISIN: AT0000612601
WKN: A0D8HW
Index: ATX Prime, ATX
Börsen: Wien / official market